CAMBRIDGE, Mass.--(BUSINESS WIRE)--
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of
investigational RNA interference (RNAi) therapeutics, today announced
that the Company will release its second quarter 2016 financial results
after market close on Thursday, August 4, 2016.
Management will conduct a conference call at 4:30 p.m. ET that day to
discuss the Company's financial results and provide a general business
update. The conference call will be webcast live via the Internet and
will be available on the "Investors & Media" section of the Dicerna
The webcast will also be archived on the Company's website.
The call can also be accessed by dialing (855) 453-3834 or (484)
756-4306 (international), and referencing conference ID 49039068 prior
to the start of the call. After the conference call, a replay will be
available until August 11, 2016. To access the replay, please dial (855)
859-2056 or (404) 537-3406, and refer to conference ID 49039068.
About Dicerna Pharmaceuticals, Inc.
Dicerna Pharmaceuticals, Inc., is an RNA interference-based
biopharmaceutical company focused on the discovery and development of
innovative treatments for rare, inherited diseases involving the liver,
for other therapeutic areas in which the liver plays a key role, and for
cancers that are genetically defined. The Company is using its
proprietary RNA interference (RNAi) technology platform to build a broad
pipeline in these therapeutic areas. In many cases, Dicerna is pursuing
targets that have historically been difficult to inhibit using
conventional approaches, but where connections between targets and
diseases are well understood and documented. The Company intends to
discover, develop and commercialize these novel therapeutics either on
its own or in collaboration with pharmaceutical partners. For more
information, please visit www.dicerna.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160728005205/en/
Rx Communications Group
Van Rees, 973-442-1555 ext. 111
Source: Dicerna Pharmaceuticals, Inc.
News Provided by Acquire Media